Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2468 participants.
Also called NCT05577988
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose other
- Phase
- Phase 3
- Enrolled
- 2,468 participants
- Registry
-
NCT05577988
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Recruiting
Technical summary
Registry record NCT05577988. Randomized; single masking; primary purpose other. Start 2024-06-18 (actual); primary completion 2027-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome
- Acronym
- ADEN
- Condition
- MYOCARDIAL INFARCTION
- Intervention (Other)
- single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Collaborator
- Fonds de Dotation ACTION
Record details
- Record id
cardio:ct-nct05577988- Content hash
2ea4b8e92de9cf1cd4c34310ddb7ddcaae102195971aa8af04e0fa03eb1da0a5